Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Deffered Revenue (2021 - 2025)

Autolus Therapeutics (AUTL) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $253.4 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Non-Current Deffered Revenue rose 10.92% year-over-year to $253.4 million, compared with a TTM value of $253.4 million through Mar 2025, up 10.92%, and an annual FY2024 reading of $244.6 million, up 43.13% over the prior year.
  • Non-Current Deffered Revenue was $253.4 million for Q1 2025 at Autolus Therapeutics, up from $244.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $253.4 million in Q1 2025 and bottomed at $47.0 million in Q4 2021.
  • Average Non-Current Deffered Revenue over 5 years is $170.9 million, with a median of $170.9 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue soared 167.78% in 2022, then increased 10.92% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $47.0 million in 2021, then skyrocketed by 167.78% to $125.9 million in 2022, then surged by 35.74% to $170.9 million in 2023, then skyrocketed by 43.13% to $244.6 million in 2024, then rose by 3.61% to $253.4 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for AUTL at $253.4 million in Q1 2025, $244.6 million in Q4 2024, and $248.9 million in Q3 2024.